Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Avastin

(bevacizumab)

16 ML bevacizumab 25 MG/ML Injection [Avastin]4 ML bevacizumab 25 MG/ML Injection [Avastin]

NO BLACK BOX WARNING

Dosage & administration

Withhold for at least 28 days prior to elective surgery. Do not administer Avastin for 28 days following major surgery and until adequate wound healing.

Metastatic colorectal cancer

* 5 mg/kg every 2 weeks with bolus-IFL
* 10 mg/kg every 2 weeks with FOLFOX4
* 5 mg/ kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line bevacizumab product-containing regimen

First-line non–squamous non–small cell lung cancer

* 15 mg/kg every 3 weeks with carboplatin and paclitaxel

Recurrent glioblastoma

* 10 mg/kg every 2 weeks

Metastatic renal cell carcinoma ( 2.5)

* 10 mg/kg every 2 weeks with interferon alfa

Persistent, recurrent, or metastatic cervical cancer

* 15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan

Stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection

* 15 mg/kg every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles

Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

* 10 mg/kg every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan given every week
* 15 mg/kg every 3 weeks with topotecan given every 3 weeks

Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

* 15 mg/kg every 3 weeks with carboplatin and paclitaxel for 6-8 cycles, followed by 15 mg/kg every 3 weeks as a single agent
* 15 mg/kg every 3 weeks with carboplatin and gemcitabine for 6-10 cycles, followed by 15 mg/kg every 3 weeks as a single agent

Hepatocellular Carcinoma

* 15 mg/kg after administration of 1,200 mg of atezolizumab every 3 weeks

Administer as an intravenous infusion after dilution. See full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions

Avastin clinical details

Efficacy: Metastatic Colorectal Cancer (mCRC)

Safety Profile: Metastatic Colorectal Cancer (mCRC)

Dosing: Metastatic Colorectal Cancer (mCRC)

Mechanism of Action (MOA)

Efficacy: Non–Small Cell Lung Cancer (NSCLC)

Safety Profile: Non–Small Cell Lung Cancer (NSCLC)

Dosing: Non–Small Cell Lung Cancer (NSCLC)

Efficacy: Metastatic Kidney Cancer (mRCC)

Safety Profile: Metastatic Kidney Cancer (mRCC)

Dosing: Metastatic Kidney Cancer (mRCC)

Efficacy: Advanced Cervical Cancer (CC)

Safety Profile: Advanced Cervical Cancer (CC)

Dosing: Advanced Cervical Cancer (CC)

Efficacy: Ovarian Cancer (OC)

Safety Profile: Ovarian Cancer (OC)

Dosing: Ovarian Cancer (OC)

Efficacy: Recurrent Glioblastoma (GBM)

Safety Profile: Recurrent Glioblastoma (GBM)

Dosing: Recurrent Glioblastoma (GBM)

drug label

Avastin prescribing information

Have more Avastin questions?

Submit MSL Request

Learn More

Need to report an Avastin issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Avastin Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Patient Consent Form

Patient Consent Form - Spanish

Learn More

Benefits investigation

Avastin Prescriber Service & Patient Consent Form

Avastin Prescriber Service Form - Online Portal

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Avastin Financial assistance options

Co-pay savings program

commercial only

Avastin Prescriber Service & Patient Consent Form

Enroll in Patient Savings Program

Avastin Prescriber Service Form - Online Portal

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Avastin Prescriber Service & Patient Consent Form

Genentech Patient Foundation Application Form (1/2)

Genentech Patient Foundation Application Form (2/2) - Patient Consent Form

Avastin Prescriber Service Form - Online Portal

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Avastin Patient education

Getting started on Avastin

NOT PROVIDED BY BRANDInstructions For Use: Metastatic Colorectal Cancer (mCRC)

NOT PROVIDED BY BRANDInstructions For Use: Non–Small Cell Lung Cancer (NSCLC)

NOT PROVIDED BY BRANDInstructions For Use: Metastatic Kidney Cancer (mRCC)

NOT PROVIDED BY BRANDInstructions For Use: Advanced Cervical Cancer (CC)

NOT PROVIDED BY BRANDInstructions For Use: Ovarian Cancer (OC)

NOT PROVIDED BY BRANDInstructions For Use: Recurrent Glioblastoma (GBM)